CSL (OTCMKTS:CSLLY) Stock Rating Upgraded by Zacks Research

CSL (OTCMKTS:CSLLY) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Separately, Canaccord Genuity Group raised CSL to a “hold” rating in a report on Monday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, CSL presently has a consensus rating of “Moderate Buy”.

CSL Stock Down 0.2%

CSL stock opened at $71.23 on Monday. CSL has a 52 week low of $61.06 and a 52 week high of $100.75. The business’s 50-day moving average price is $69.95 and its 200 day moving average price is $76.54. The company has a quick ratio of 1.12, a current ratio of 2.46 and a debt-to-equity ratio of 0.50.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.